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 Abstract 
INJECTION DRUG USE AMONG WEST 
VIRGINIA MEDICAID BENEFICIARIES: 
AN ANALYSIS OF HEALTH OUTCOMES, 
SERVICE UTILIZATION, AND COST 
Michael J. Cima 
In the United States, injection drug use is a serious public health concern associated with 
an array of negative health outcomes and substantial financial consequences for systems 
of care. The purpose of this study was to characterize a statewide sample of Medicaid 
insured persons who inject drugs in terms of health outcomes, service utilization and cost. 
A cross-sectional, retrospective analysis of West Virginia Medicaid claims data between 
2014 and 2016 was conducted. Between 2014 and 2016, 5,082 West Virginia Medicaid 
beneficiaries amassed 14,414 service visits, among which inpatient, emergency room, 
and mental health and substance abuse were the most common. Drug poisonings 
(n=5,077), soft-tissue infections (n=4,127) and other infectious diseases (n=2,141) were 
the most common clinical conditions within this sample.  Medicaid claims data were not 
a suitable proxy for state surveillance data as it pertains to new cases of Hepatitis B, 
Hepatitis C, HIV and heroin overdoses. Ordinal logistic regression results indicate that 
infectious diseases like endocarditis and soft-tissue infections are associated with 
increased service utilization. Similarly, multiple regression models show increased cost 
among individuals with HIV, endocarditis, and Hepatitis B. Preventative services, e.g. 
syringe exchange programs, are important tools to reducing the spread of infectious 
diseases, and thereby decrease frequent service utilization and cost among injection drug 
users. 
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C H A P T E R  1 :  I N T R O D U C T I O N  
Persons who inject drugs (PWID) are subject to a myriad of adverse health outcomes, 
including overdose, withdrawal, viral hepatitis, human immunodeficiency virus (HIV), 
endocarditis, and other soft tissue infections. (Alter & Moyer, 1998; Binswanger, Kral, 
Bluthenthal, Rybold, & Edlin, 2000; CDC, 2016; Rudd, Seth, David, & Scholl, 2016) Recent 
nationwide increases in opioid overdoses, acute hepatitis C viral infection (HCV), and an HIV 
outbreak among PWID emphasize the urgency of the injection drug use (IDU) epidemic in the 
United States (US). (Conrad, Bradley, Broz, Buddha, Chapman, Galang, Hillman, Hon, Hoover, 
Patel, Perez, Peters, Pontones, Roseberry, Sandoval, Shields, Walthall, Waterhouse, Weidle, Wu, 
& Duwve, 2015; Rudd, Aleshire, Zibbell, & Gladden, 2016; Zibbell, Iqbal, Patel, Suryaprasad, 
Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, & Holtzman, 2015) Between 2002 
and 2013, the United States heroin overdose death rate more than tripled, from 0.7 to 2.7 per 
100,000 people. (Rudd, Seth, et al., 2016) Concurrently, the leading infectious disease killer in 
HCV infection increased throughout the US, with the most notable increases occurring among 
PWID in rural states including Kentucky and West Virginia (WV) located in central Appalachia. 
(Ly, Hughes, Jiles, & Holmberg, 2016; Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-
Moravian, Serrecchia, Blankenship, Ward, & Holtzman, 2015) In 2015, the Indiana State 
Department of Health reported a 181 case outbreak of HIV in a rural community where the 
sharing of injection equipment was a contributing factor in 92% of reported cases resulting in 
92% of persons coinfected with HCV. (Peters et al., 2016) Additionally, invasive bacterial 
infections like endocarditis and other soft tissue infections resulting from direct injection into the 
skin or muscle continue to be one of the most common recurring problems among PWID, and is 
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costly to healthcare institutions and insurers. (Binswanger et al., 2000; Fleischauer, Ruhl, Rhea, 
& Barnes, 2017; Tookes, Diaz, Li, Khalid, & Doblecki-Lewis, 2015) 
While adverse health outcomes related to IDU have increased throughout the US, studies 
indicate nonurban and rural areas have been disproportionately impacted over the past ten years. 
(Des Jarlais et al., 2015; Suryaprasad et al., 2014; Zibbell, Iqbal, Patel, Suryaprasad, Sanders, 
Moore-Moravian, Serrecchia, Blankenship, Ward, & Holtzman, 2015) Rural Appalachia, in 
particular, has experienced the most pronounced increases in HCV, HIV, and overdoses among 
PWID. A recent study, ranking US counties in terms of vulnerability to the spread of IDU related 
HCV and HIV identified the most vulnerable counties were largely rural and in the Appalachian 
region. (Van Handel et al., 2016) Highly effective and cost containing public health interventions 
to counter IDU associated events have been identified in both rural and urban areas of the world, 
including syringe and injection equipment exchange programs (SEP). (Kwon, Iversen, Maher, 
Law, & Wilson, 2009; D. Wilson, Taaffe, Fraser-Hurt, & Gorgens, 2014; D. P. Wilson, Donald, 
Shattock, Wilson, & Fraser-Hurt, 2015) 
SEPs reduce IDU health risks via a harm reduction approach, without the explicit primary 
objective of IDU cessation. (Bastos & Strathdee, 2000; Kwon et al., 2009; Vickerman et al., 
2006; D. P. Wilson et al., 2015) Nonetheless, multiple studies identified decreasing incidence of 
HIV and HCV in locations with SEP and increases in locations without SEPs. (D. P. Wilson et 
al., 2015) SEPs offer a range of services which may include education, counseling, STI testing, 
distribution of condoms, legal services, and opioid substitution treatment. Some of these 
services, e.g. peer based education interventions, are also effective in reducing IDU risk 
behaviors, such as sharing injection equipment. (Mackesy-Amiti et al., 2013)Compared to other 
prevention strategies, SEPs are relatively inexpensive to implement and sustain, with an 
 3 
 
estimated cost ranging between $23-$71 (US) per person, per visit depending on location and 
services offered with the return on investment of approximately $5 saved to every $1 spent. 
(Kwon et al., 2009; D. Wilson et al., 2014; D. P. Wilson et al., 2015)This return on investment 
was based on the dollars saved for preventing at least one infection such as HIV, HCV, and/or 
other soft tissue infections compared to dollars spent on equipment and services.  
While SEPs are demonstrably effective, these services have not diffused widely in the 
US, either rural or urban. According to the results of a recent, nationwide study of SEPs from 
various regions of the US, fewer SEPs were located in rural (30 SEPs) areas compared to urban 
(105 SEPs) areas. (Des Jarlais et al., 2015) Further, half of rural SEPs were categorized as 
“small” or “medium”, and exchanged far fewer syringes per program than their urban 
counterparts (medians of 55,000 syringes exchanged vs. 146,263 syringes exchanged)   In terms 
of operating characteristics, rural SEPs report fewer mobile exchanges, more problems with 
procuring funding, reaching participants, and fewer full-time personnel. (Des Jarlais et al., 2015) 
Additionally, the federal ban on funding components of SEPs persists ("Public Health and 
Welfare Act," 1988), thus potentially limiting the availability of services and resources.  The lack 
of prevention services for PWID in rural areas is an important disparity which not only directly 
affects public health, but also increases the amount of money spent on healthcare by insurers, 
including Medicaid.  
There is an established link between IDU and poverty in wealthy countries. (Crime, 
2016) With the expansion of Medicaid, a government subsidized health insurance program, 
under the Affordable Care Act (ACA) in 2010, health insurance is more available to millions of 
lower income Americans, decreasing uninsured adults. (Blumenthal, Abrams, & Nuzum, 2015) 
In states with expanded coverage, individuals with a household income at or below 133% of the 
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federal poverty level (FPL) are eligible for Medicaid. (Blumenthal et al., 2015) Therefore, 
Medicaid expansion may result in more PWID receiving coverage. Even prior to Medicaid 
expansion, studies have shown that PWID are often covered by Medicaid when eligible. 
(Fleischauer et al., 2017; Takahashi, Baernstein, Binswanger, Bradley, & Merrill, 2007; Tookes 
et al., 2015) In these studies, Medicaid was billed for a majority of the injection drug-related 
services rendered, and these services tended to be more expensive than services for other patients 
during the same time. One study estimated the average cost per hospitalization for PWID with 
soft-tissue infections, like abscesses and cellulitis, was $4,449 compared to $3,540 for non-IDU 
related hospitalizations (US). (Takahashi, Maciejewski, & Bradley, 2010) In another similar 
study, costs of treating endocarditis among PWID exceed $50,000, and were billed to Medicaid 
for 42% of the time. (Fleischauer et al., 2017) 
 
1.1  Problem Statement 
Emergency and other care costs for persons who inject drugs are increasingly covered by 
Medicaid expansion and other publicly funded programs. (Tookes et al., 2015) Few studies have 
utilized individual level Medicaid data from a rural state to assess care costs and utilization. Use 
of Medicaid claims data may provide a unique opportunity to address gaps in knowledge 
surrounding service utilization and associated costs within this hard to reach population.  
1.2  Conceptual Framework for the Study 
Several studies use claims data to investigate various issues related to drug abuse. 
(Birnbaum et al., 2011; Dufour et al., 2014; McAdam-Marx, Roland, Cleveland, & Oderda, 
2010; Shei et al., 2015; White et al., 2005) The methodology of a majority of these studies 
involves retrospectively querying claims databases, using ICD-9 & ICD-10 codes, in order to 
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describe the prevalence and cost of opioid drug abuse among an insured population. As of 
October 1, 2015, the United States shifted from ICD-9 to ICD-10 codes. (CDC, 2017) Studies 
querying claims databases with ICD codes generally show that the prevalence of opioid abuse 
has increased, (Dufour et al., 2014) opioid abusers tend to have more comorbidities, (McAdam-
Marx et al., 2010; Shei et al., 2015) and costs associated with opioid abuse are significant. 
(McAdam-Marx et al., 2010; White et al., 2005) However, the current body of research 
surrounding claims data and drug abuse focuses predominantly on prescription opioid abuse, 
perpetuating the gap in IDU, which is further exacerbated by a paucity of research with a focus 
on rural IDU.  
This study builds on the opioid drug foundation using a previously established (Tookes et 
al., 2015) methodological framework to focus on the IDU epidemic in a rural US state. ICD-9 & 
ICD-10 codes specific to outcomes associated with IDU will be used to define IDU for this 
study. Additionally, the ICD codes will serve as a basis for retrospectively querying a Medicaid 
claims database. Services, health outcomes, and patient characteristics will be described in terms 
of frequency and cost. This project provides an opportunity to develop a more detailed view of 
insured PWID.    
 
1.3  Purpose of the Study 
The proposed study investigates the public health and economic consequences of the IDU 
epidemic as supported by West Virginia Medicaid data. The frequency of injection drug-related 
health outcomes, service type, charge, and patient characteristics will be described. Specifically, 
this project seeks to identify if Medicaid claims data have utility for investigating issues 
experienced by a hard to reach population specifically PWID. Previous studies show that PWID 
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tend to use emergency departments as primary care, and present late during the course of disease. 
(Palepu et al., 2001) These issues combined with a previous lack of widespread electronic 
medical record utilization has created a challenge in identifying complete data sources for this 
population. As Medicaid expansion provides coverage to many lower income persons, an 
opportunity to increase knowledge among multiple medically fragile groups presents itself. 
(Blumenthal et al., 2015) The proposed study will create a comprehensive profile of a statewide 
sample of Medicaid insured PWID, including a description of the most frequent and costly 
services accessed, health outcomes related to IDU and sociodemographic characteristics 
associated with poor outcomes, frequent service usage, and high cost.  
 
1.4  Specific Aims and Objectives 
Aim 1: Determine the efficacy of state Medicaid data as a proxy for disease surveillance data in 
estimating the number of drug overdoses and injection drug related infections in WV between 
2014 and 2016. 
1. Quantify and describe overdoses, and IDU associated infections among WV Medicaid 
beneficiaries who received services related to IDU between 2014 and 2016. 
2. Compare rates and proportion of overdose and IDU associated infections obtained from 
Medicaid claims data to surveillance data. 
Aim 2: Examine service utilization and characteristics of WV Medicaid beneficiaries who inject 
drugs between 2014 and 2016.  
1. Describe the economic, demographic, and service utilization characteristics of WV 
Medicaid beneficiaries who received services related to IDU between 2014 and 2016. 
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2. Assess the relationship between frequent service utilization and patient characteristics. 
Aim 3: Examine the cost of service utilization of WV Medicaid beneficiaries who inject drugs 
between 2014 and 2016.  
1. Quantify the total cost of services, the costliest services, and describe the geographic 
distribution among PWID and who are covered by Medicaid between 2014 and 2016. 
2. Assess the relationship between total costs and patient characteristics and diagnoses. 
 
1.5  Procedures 
 The sample for the proposed project will be comprised of WV Medicaid beneficiaries 
who have received IDU-related services between 2014 and 2016. This date range was chosen 
based on the state Medicaid expansion coverage under the ACA began January 1, 2014.  
Inclusion in this study will be based on specific criteria to determine whether a person injects 
drugs and if they have experienced an outcome related to IDU.  ICD-10 codes will serve as the 
basis for these criteria. Relevant data elements will be formally requested from the WV 
Department of Health and Human Services (DHHR), Bureau for Medical Services (BMS), which 
is charged with operating WV Medicaid and maintaining data. The individual level data that 
results from the request will not contain any personally identifiable information. Appropriate 
analyses will be conducted to accomplish each aim and subsequent objective outlined previously.  
 
1.6  Significance  
 Without access to sterile injection equipment and other services offered by harm 
reduction programs, PWID are more susceptible to adverse health outcomes leading to increased 
 8 
 
morbidity and mortality. (Grebely & Dore, 2014) Costs associated with providing emergency 
and recurring IDU-related services to PWID are substantial, and increasingly billed to Medicaid. 
(Takahashi et al., 2007; Tookes et al., 2015)  These factors support the need for a shift towards 
preventative care and services for PWID.  However, harm reduction services are considerably 
less common in rural areas, where it has been shown there is a significant need. (Des Jarlais et 
al., 2015) West Virginia continues to struggle with the consequences of IDU, and consistently 
reports some of the highest rates of overdoses and related infections in the US. (Rudd, Aleshire, 
et al., 2016; Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-Moravian, Serrecchia, 
Blankenship, Ward, & Holtzman, 2015) 
 Increasing the knowledge within West Virginia of these issues by creating a 
comprehensive profile of Medicaid beneficiaries who inject drugs by assessing and describing 
the services received, inclusive of charges, and the geographic distribution of services indicate 
where prevention strategies, such as harm reduction, could be most useful. As the predominant 
insurer of PWID nationally, Medicaid programs can benefit from this information to identify 
avenues for improving healthcare access and containing costs. Additionally, given the paucity of 
information available on PWID in rural areas, the proposed project will add valuable information 
to the current body of research. 
 
1.7  Limitations 
 There are limitations to the proposed study. First, this study will use ICD-9 codes to 
determine beneficiary IDU status and related adverse health outcomes. Some studies suggest that 
using ICD-9 or -10 codes for research could result in the underreporting of certain conditions. 
(G. Jones et al., 2012) This may be exacerbated when dealing with complex behaviors like IDU, 
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since it can be difficult to ascertain route of drug use from ICD-9 codes. Another drawback to 
this study design is the retrospective, secondary data analysis component using data not 
originally collected for research. Because of this, it is not always possible to include all 
necessary data elements for the analyses to control for issues like confounding.  This study will 
only include PWID who are or were insured by Medicaid between 2014 and 2016. Consequently, 
PWID who are covered by private insurance or have no insurance coverage will not be included. 
Past research suggests that this could include a significant proportion of the total population of 
PWID. (CDC, 2015b; Tookes et al., 2015) Not including those who are uninsured or are insured 
by plans outside of Medicaid could diminish the generalizability of the proposed study.  
 
1.8  Organization  
 The proposed study will be organized as four separate chapters to include: an extensive 
literature review (Chapter two), methods section (Chapter three), relevant results (Chapter four), 
and discussion of and conclusions drawn from results (Chapter five).  Chapter two will include a 
systematic approach to reviewing the current body of research surrounding drug use among 
Medicaid beneficiaries. Chapter three will discuss the methods employed in defining the study 
sample, obtaining data, and analyzing data. Chapter four will present the results obtained from 
analyses in tables, figures, and paragraph form. Finally, chapter five will elaborate on results, 
synthesize appropriate conclusions, and make recommendations for future research.  
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C H A P T E R  2 :  L I T E R A T U R E  R E V I E W  
The US injection drug use (IDU) epidemic is a public health concern associated with negative 
health outcomes and substantial financial consequences for systems of care. Specifically, IDU is 
associated with increased overdose deaths, infectious diseases, and cost to healthcare institutions 
and government subsidized insurers like Medicaid. (Kwon et al., 2009; Rudd, Aleshire, et al., 
2016; Takahashi et al., 2010; D. P. Wilson et al., 2015; Zibbell, Iqbal, Patel, Suryaprasad, 
Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, Holtzman, et al., 2015) This study 
seeks to understand the factors associated with the health and financial consequences of IDU 
using individual level service of IDUs in the state.   
 
2.1 U.S. Drug Use 
Prescription opioid pain relievers and heroin are opioids that are considered the driving 
force behind the substantial increase in overdose deaths in the US. Between 1999 and 2015, 
overdose (OD) rates for prescription opioids and heroin have nearly quadrupled, resulting in 
more than 500,000 deaths. (C. M. Jones, Logan, Gladden, & Bohm, 2015) In 2015 over 50,000 
drug overdose deaths (ODD) occurred; 30,000 of which were opioid attributable, marking the 
highest annual ODDs in US history and a nearly three-fold increase since 2002. (Rudd, Seth, et 
al., 2016) Between 2014 and 2015, states in the North and Southeast census regions experienced 
statistically significant (p-value <0.05) increases in ODDs, including: West Virginia (41.5 per 
100,000), New Hampshire (34.3 per 100,000), Kentucky (29.9 per 100,000), Ohio (29.9 per 
100,000), and Rhode Island (28.2 per 100,000). (CDC National Vital Statistics System, 2016; 
Rudd, Seth, et al., 2016) Adults aged 25 to 64 have the highest ODD rates, however, ODDs 
increased specifically among 25 to 34 year olds, and men and white, non-Hispanics since 2010. 
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(Rudd, Seth, et al., 2016) Also during this time, heroin ODDs increased by more than 20% 
nationwide with each census region reporting a statistically significant increase. (CDC National 
Vital Statistics System, 2016) Consistent with other drug OD, men between the ages of 25 and 
44 had the highest heroin ODs. However, heroin ODD rates are increasing among groups with 
historically low rates, such as persons aged 18 to 25 years, women, and persons with higher 
income. (CDC, 2015b)  These trends for heroin ODs, specifically, contribute to the growing 
importance of IDU in the US.  
2.2 U.S. IDU 
 IDU is associated with multiple complications in addition to ODs, including economic 
distress, spread of infectious diseases, mental illness, and reduced access to care. (Centers for 
Disease & Prevention, 2012; Palepu et al., 2001; Richardson, Wood, Li, & Kerr, 2010) Given the 
upward trend of IDU across the US, the effects of these complications could become more 
pronounced for not only PWID, but also healthcare institutions and insurers. 
 2.2.1 Associated Social and Economic Factors 
  Economic distress, unemployment and decreased social functioning are significant 
aspects of IDU. (Richardson et al., 2010) Studies consistently report an inverse association 
between IDU and employment, and typically characterize PWID as an impoverished population. 
For example, one recent, nationally representative study found a strong association between 
unemployment and illicit drug use.  (Compton, Gfroerer, Conway, & Finger, 2014) Additionally, 
another study reported a poverty rate in excess of 60% for a particular cohort of PWID. (Cooper 
et al., 2016).  
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 Homelessness has long been tied IDU through overlapping risk factors such as poverty, 
incarceration, and mental health. (Briggs et al., 2009; Linton, Celentano, Kirk, & Mehta, 2013; 
Mizuno et al., 2009) Additionally, evidence supports a temporal relationship between 
homelessness and IDU initiation or relapse. One recent study found that among those who had 
stopped injecting, homelessness was associated with IDU relapse, regardless of the duration of 
homelessness. (Linton et al., 2013) Further, homelessness was also associated with injection-
related risk behaviors, including needle and cotton sharing, as well as mental illness.  
 In the US, drug policy seemingly centers on the idea that arrests deter drug-related crimes 
and drug use in general. (Friedman et al., 2011) Consequently, the US has one of the highest 
rates of drug-related incarcerations compared to similar countries, with 46% of all federal 
offenses relating to drug use. (Prisons, 2017) However, evidence from recent studies suggests 
that increasing arrests for drug crimes does not decrease drug use, and is costly.  One estimate 
puts the cost per inmate at over $20,000, which translates to nearly $12 billion to incarcerate 
inmates with drug-related offenses. (Warren, Gelb, Horowitz, & Riordan, 2008) 
2.2.2 Associated Comorbidities 
PWID who share injection equipment with infected persons are at an increased risk for 
bloodborne pathogens, including HIV, viral hepatitis, and soft-tissue infections, like cellulitis 
and abscesses. In some studies, the estimated prevalence of hepatitis C (HCV), hepatitis B 
(HBV), and HIV among IDUs was as high as 77%, 66%, and 21% respectively. (Garfein, 
Vlahov, Galai, Doherty, & Nelson, 1996; Spiller et al., 2015; Zibbell, Iqbal, Patel, Suryaprasad, 
Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, Holtzman, et al., 2015) HIV/HCV 
coinfection is also common among IDUs, with rates found as high as 92%. (Peters et al., 2016; 
Platt et al., 2016) In co-infected persons, HCV may transmit more efficiently, including 
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increased risk for perinatal transmission by infected mothers. (Platt et al., 2016) Coinfection can 
complicate HIV treatment leading to antiretroviral related hepatotoxicity. (Platt et al., 2016; 
Shepard, Finelli, & Alter, 2005) Risky behavior engagement, such as unprotected sex, social 
issues, including unstable housing, lack of access to care, limited availability of sterile injection 
equipment, and decreased availability of treatment programs, and other societal and healthcare 
related factors contribute to the spread of infectious diseases. (Altice, Kamarulzaman, Soriano, 
Schechter, & Friedland, 2010; Burris & Strathdee, 2006; Centers for Disease & Prevention, 
2012; Chander, Himelhoch, & Moore, 2006; Friedland, 2010; Gebo, Keruly, & Moore, 2003; 
Regier et al., 1990; Rhodes, Singer, Bourgois, Friedman, & Strathdee, 2005).  
In addition to infectious diseases, PWID tend to have higher rates of depression, 
personality, and/or anxiety disorders, as well as polysubstance abuse and history of adverse 
childhood events, which pose significant obstacles to improving health outcomes. (Mackesy-
Amiti, Donenberg, & Ouellet, 2012, 2014; Sansone, Whitecar, & Wiederman, 2009) One study 
reports the prevalence of major mental health disorders at more than one third among PWID. 
(Kidorf et al., 2004)  In particular, 25% of adults with Schizophrenia have reported illicit drug 
use in their lifetime. (Van Dorn, Desmarais, Young, Sellers, & Swartz, 2012) These psychiatric 
disorders have been shown to be associated with certain IDU risk behaviors, including injection 
equipment sharing with a high number of people, sharing with strangers, and with people known 
to be HIV-infected. (Kidorf et al., 2010; Mackesy-Amiti et al., 2014) 
2.2.3 Care Access, Utilization, and Economic Impact of IDU 
Poor access to healthcare and service utilization is a well-documented problem for 
PWID. (Chitwood, McBride, French, & Comerford, 1999; McCoy, Metsch, Chitwood, & Miles, 
2001) PWID generally have low access to primary care for a multitude of reasons, including 
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inability to set and keep appointment times. Consequently, PWID may use emergency 
departments as their primary source of healthcare, resulting in later disease stage presentation for 
care and higher costs. (Fairbairn et al., 2012; French, McGeary, Chitwood, & McCoy, 2000; 
Palepu et al., 2001; Solomon, Frank, Vlahov, & Astemborski, 1991) For example, in one 
Canadian-based IDU cohort study, 60% of PWID were frequent users of the emergency 
department (at least three visits).  Among all PWID accessing the emergency department, HIV-
positive persons were more likely to be frequent users (adjusted OR 5.4, 95% CI 3.4-8.6), and 
have higher costs. (Palepu et al., 2001) 
The economic impact of treating IDU related complications can be substantial as it 
includes infectious diseases, which are largely preventable with access to sterile to injection 
equipment. In addition to serious medical consequences associated with HIV, including 
weakened immune system, susceptibility to opportunistic infections, transmissibility, and death, 
the price of treating one new case into perpetuity is especially burdensome. Treating one HIV 
case costs approximately $38,000 per year, with considerable variation dependent on disease 
stage. (Fleishman, Monroe, Voss, Moore, & Gebo, 2016) Further, the most recent available data 
estimates the total lifetime cost of treating one case of HIV to be between $253,000 and 
$402,000 depending on disease stage. (Farnham et al., 2013) Considering that approximately 
9%, or 3,600 new cases of HIV in the US each year identify IDU as risk factor, approximately 
$136.8 million are spent on new HIV infections just among PWID. (CDC, 2016) 
With more than 60% of HCV cases reporting IDU as a risk factor, the financial 
considerations of IDU and HCV is equally important. Until recently, HCV was a chronic 
condition that typically lasted for the infected patient’s lifetime. However, with the advent of 
direct acting antivirals (DAAs), HCV is curable in a large percentage of people. A drawback to 
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these drugs is the price of the regimens. In the US, certain DAA drugs, such as sofosbuvir, cost 
as much as $84,000 for a 12-week regimen, or approximately $1,000 per pill. (Rosenthal & 
Graham, 2016) The most recent available data indicate more than 2,100 acute HCV diagnoses in 
2014, which translates to over $176 million spent on treating HCV among PWID yearly. (CDC, 
2014) Moreover, with increasing cure rates comes the possibility of relapse, thus further 
exacerbating the financial burden of treating HCV.  
Although HBV is vaccine preventable, for persons without vaccination, there still is a 
financial burden associated with treatment. One cost analysis reported the range of costs for 
treating HBV according to complications and disease stages. (Lee, Veenstra, Iloeje, & Sullivan, 
2004) According to this study, the annual cost for treating chronic HBV was $761 per patient; 
decompensated cirrhosis because of HBV was $11,459 per patient; liver transplant was $86,552 
per patient; transplant follow-up care was $12,560 per patient; and hepatocellular carcinoma was 
$7,533 per patient. 
Soft-tissue infections and endocarditis are common among PWID who do not have access 
to sterile injection equipment. One study reported that a third of PWID were treated for soft-
tissue infections like cellulitis and abscesses. (Binswanger et al., 2000) Hospitalizations among 
PWID with soft-tissue infections can result in significant costs with one recent study estimate of 
$4,449. (Takahashi et al., 2010) Further, another study reported that over a one-year period, 
PWID treated for soft-tissue infections at a single hospital incurred $11.4 million in charges. 
(Tookes et al., 2015) Additionally, 41% of these charges were billed to Medicaid, the largest 
insurer for this group. (Tookes et al., 2015) Similarly, endocarditis among PWID has increased 
over the past decade, with high costs billed predominantly to Medicaid. In a recent study, PWID 
presenting to a single hospital incurred over $50,000 per hospitalization for endocarditis, and 
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most (42%) were insured by Medicaid. (Fleischauer et al., 2017) Although soft-tissue infections 
are acute and readily treatable, the cost of consistently treating PWID is formidable combined 
again with late stage presentation for care.  
Despite poor primary care utilization among PWID and subsequently higher costs, 
effective public health interventions, such as harm reduction can alleviate some negative health 
outcomes and reduce costs. Harm reduction refers to strategies aimed at diminishing health risks 
associated with behaviors like IDU. (D. P. Wilson et al., 2015) When considering harm reduction 
for IDU, syringe exchange programs (SEP) are one of the more common methods employed, and 
seek to reduce the spread of bloodborne pathogens and soft-tissue infections. The underlying 
function of SEPs involves the distribution of sterile needles, syringes, and injection equipment to 
PWID, while collecting and safely discarding used paraphernalia.  
SEPs implemented in a variety of locations worldwide and in the US have been effective 
in reducing the spread of infectious diseases. (Bastos & Strathdee, 2000; Kwon et al., 2009; 
Vickerman et al., 2006; D. P. Wilson et al., 2015) A systematic review conducted by Wodak et al 
found 23 studies reported SEPs reduced risk behaviors associated with HIV. (Wodak & Cooney, 
2005) In particular, one of those studies reported significant decreases in HIV incidence after the 
implementation of a SEP (4% - 1%). (Jarlais et al., 2005) Other studies have found as much as an 
80% reduction in HIV, HCV, and other bloodborne pathogen incidence among those began 
injecting drugs after the implementation of SEPs. (Somaini et al., 2000) 
 SEPs are successful in reducing the spread of infections because of the effectiveness in 
reducing the sharing of needles and equipment. A number of studies report PWID who also 
participate in SEPs are less likely to self-report sharing needles, syringes or injection equipment. 
One of those studies found a protective effect of participation in a SEP on sharing behavior 
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(aOR= 0.77, 95% CI=0.67-0.88). (Holtzman et al., 2009) Similarly, a separate study found that 
participation in a SEP reduced the odds of receptive needle sharing by nearly 60% (OR=0.33 
CI=0.23-0.46), lending needles by 45% (OR= 0.55 CI=0.41-0.75), and sharing equipment by 
30% (OR= 0.70 CI=0.52-0.95). (Huo & Ouellet, 2007). Another important function of SEPs is 
the collection and disposal of used needles or syringes, ensuring the potentially hazardous 
materials are discarded appropriately, further reducing sharing behaviors and risk to the general 
public. However, relatively few US-based studies have investigated needle return rates at SEPs. 
(Ksobiech, 2004) One literature review found that of US-based studies, the overall average 
needle return rate was approximately 90%. (Ksobiech, 2004) Although, there was significant 
variation between studies (68%-102%). (Paone, Jarlais, Caloir, Clark, & Jose, 1995)  
The evidence supporting the effectiveness of SEPs in reducing the spread of bloodborne 
pathogens and other infections among PWID is abundant. (Holtzman et al., 2009; Hurley, Jolley, 
& Kaldor, 1997; Jarlais et al., 2005; Kwon et al., 2009) In addition, SEPs tend to be a cost-
effective intervention by averting costs of new infections while costing relatively little to operate. 
(D. P. Wilson et al., 2015) According to one estimate, implementing and maintaining a SEP costs 
approximately $23-$71 per person accessing services per year. (D. Wilson et al., 2014) Further, 
one study found that in addition to significantly reducing HIV incidence, a SEP reported an 
approximate $5 saved as a result of infection aversion for every $1 invested in providing 
services. (Kwon et al., 2009) Moreover, considering the cost of treating new cases of HIV 
(~$136 million per year) and HCV (~$176 million per year) just among PWID, the economic 
benefits of having optimal coverage of SEP could be profound. (Farnham et al., 2013; Rosenthal 
& Graham, 2016) This is especially true for economically depressed, rural regions of the US 
where IDU is becoming more of an issue. (Des Jarlais et al., 2015) 
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IDU is a highly stigmatized behavior, and significant barriers prevent many PWID from 
accessing treatment and harm reduction services. Notable barriers include availability of 
services, distance from services, fear of police, and stigmatization among others. (Allen, Ruiz, & 
Jones, 2016; Beletsky et al., 2014) In one study, police encounters were an important barrier to 
accessing a SEP with 52% of clients having been stopped by police, 10% reporting syringe 
confiscation, resulting in persons police encounters becoming less likely to access the SEP 
(adjusted OR= 0.59; CI=0.40-0.89). (Beletsky et al., 2014) Availability of harm reduction 
services in rural areas is also of concern because of the relatively few programs in operation. 
(Des Jarlais et al., 2015) Addressing these barriers could not only improve health outcomes 
among PWID, but also reduce spending associated with increased utilization of emergency 
services and treating new bloodborne infections. 
With the passing of the Affordable Care Act in 2010 came a large-scale expansion of 
Medicaid to include more lower-income Americans. (Blumenthal et al., 2015) Medicaid is a 
government subsidized health insurance program, administered at the state-level, which provides 
coverage to low-income adults, children, and pregnant women among others. Second only to 
employer-based insurance, Medicaid is one of the largest insurers of Americans, covering 
approximately 20% of the population. (Foundation, 2015) Although there is no estimate of the 
number of PWID covered by Medicaid, indications are that it is a large proportion. A number of 
studies conducted on an array of topics related to IDU have shown that Medicaid is often the 
predominant insurer among PWID. (C. M. Jones et al., 2015; Knowlton et al., 2001; Takahashi et 
al., 2010; Tookes et al., 2015; Yehia et al., 2014) The proportion of PWID covered by Medicaid 
varied between studies, with the largest reported at approximately 60%. (Yehia et al., 2014) One 
particular study investigated health insurance status among persons with HIV were more likely 
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to be insured by Medicaid (60%) with Medicare covering 19%. (Yehia et al., 2014) The CDC 
estimates that 5% of persons who overdosed on injected heroin were Medicaid covered and this 
was the only consistent insurance coverage. (CDC National Vital Statistics System, 2016) 
2.3  IDU and Rurality 
2.3.1 IDU in Rural US  
 Rural states are disproportionately impacted with higher rates of opioid abuse. 
Traditionally considered an urban problem, rural drug abuse has increased over the past two 
decades. (Dombrowski, Crawford, Khan, & Tyler, 2016; Gfroerer, Larson, & Colliver, 2007; 
Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, 
Holtzman, et al., 2015) The most significantly impacted states are those in the rural, central 
Appalachian region which contains states with some of the highest age-adjusted rates of ODDs. 
(Rudd, Seth, et al., 2016) Although not widely reported, studies have identified important social 
and demographic differences between rural and urban drug abusers, including: age of drug use 
initiation is younger among rural drug users; persons tend to be white and non-Hispanic; and 
have different initiation patterns for IDU (Young, Havens, & Leukefeld, 2012) (Paulozzi, 2012) 
(Young et al., 2012) Heroin overdoses have permeated rural regions. Fentanyl encounters, 
specifically, are on the rise in the central Appalachian region. (CDC, 2015a) Fentanyl, a 
synthetic opioid pain reliever that can be up to 100 times stronger than morphine, is a common 
drug of choice and manufactured in a method which increases the probability of OD. (Algren et 
al., 2013) Between 2014 and 2015, fentanyl overdose death rates increased by 72%, resulting in 
9,500 deaths nationwide. (Rudd, Seth, et al., 2016) 
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2.3.2 Social and Economic Factors in Rural US 
 Compared to the rest of the US, the rural, central Appalachian region struggles with 
unemployment and economic hardship. As of 2017, the unemployment rates for certain central 
Appalachian states, like West Virginia (4.9) and Kentucky (5.0), were among the worst in the 
nation (4.5).  In 2015 median household income was significantly lower than the national 
average ($33,000 v. $53,000); and nearly 25% of central Appalachians were living in poverty 
compared to the 14% national average. (Pollard & Jacobsen, 2017)The Appalachian Regional 
Commission (ARC) created an index, using unemployment rates, poverty rates, and income, to 
assess the economic status of Appalachian counties. According to this index, in 2016, the 
majority of the 84 Appalachian counties classified as ‘economically distressed’ were in the 
central Appalachian region.  These economic characteristics factor into the current opioid 
epidemic plaguing this area. Studies have drawn a connection between economic hardship and 
substance abuse within Appalachia and abroad. (Compton et al., 2014; Richardson et al., 2010) 
The situation in post-recession Appalachia is comparable to the collapse of the Soviet Union, the 
other region in the world which has faced increased injection drug use following economic 
hardships. Following the collapse, former Soviet Union nations experienced increases in 
unemployment, depression, suicide, and substance abuse. (Atlani, Carael, Brunet, Frasca, & 
Chaika, 2000; McKee, 2005) 
2.3.3 IDU Associated Infectious Diseases: Rural v. Urban 
 IDU and infectious diseases are increasing in importance in rural areas with increased 
rates of HCV and HBV. (Suryaprasad et al., 2014) Between 2006 and 2012, there was a 364% 
increase in the number of acute cases of HCV among people 30 and younger within central 
Appalachia, which includes Kentucky, West Virginia, Tennessee, and Virginia.  Among these 
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cases, 73% indicated IDU as a risk factor. (Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-
Moravian, Serrecchia, Blankenship, Ward, Holtzman, et al., 2015) HBV increased in the same 
states while remaining stable throughout the rest of the US. (Harris et al., 2016) Between 2006 
and 2013, there was a 114% increase in acute HBV cases reported from West Virginia, 
Kentucky, and Tennessee, with a majority indicating IDU. (Harris et al., 2016) HIV infections 
among rural PWID has also been a significant issue recently. In 2015, an HIV outbreak of IDUs 
in rural Indiana led to 135 new infections with 80% reporting a history of IDU. (Conrad, 
Bradley, Broz, Buddha, Chapman, Galang, Hillman, Hon, Hoover, Patel, Perez, Peters, 
Pontones, Roseberry, Sandoval, Shields, Walthall, Waterhouse, Weidle, Wu, Duwve, et al., 
2015)  
In 2016, the CDC conducted a nationwide assessment of HCV/HIV risk among IDUs at 
the county level. (Van Handel et al., 2016) This study revealed the majority of counties at the 
highest risk for increased rates of IDU-related HCV and HIV were rural and concentrated in the 
central Appalachian region. Additionally, half of WV counties were among the most vulnerable 
to the spread of HCV and HIV among PWID, including two of the top ten most vulnerable 
counties. (Van Handel et al., 2016)  
2.3.4 Care Access: Rural v. Urban 
In general, there are significant disparities in health care access between rural and urban 
areas of the US. (Douthit, Kiv, Dwolatzky, & Biswas, 2015) Certain barriers affecting health 
care access are specific to rural regions, and include cultural and financial constraints, scarcity of 
services, lack of trained physicians, insufficient public transport, and poor availability of 
broadband internet services. (Douthit et al., 2015) Consequently, rural inhabitants tend to be in 
poorer health and have less access to a regular physician compared to their urban counterparts. 
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(Douthit et al., 2015) Similar disparities exist for rural and urban PWID, understated by the 
availability of access to harm reduction services. 
As of 2014, over 200 SEPs were in operation across the US. (Des Jarlais et al., 2015) 
However, according to a recent report, significantly fewer SEPs and harm reduction services 
were available outside of urban centers. (Des Jarlais et al., 2015) Additionally, rurally based 
SEPs exchanged far fewer needles, had smaller budgets, and were more likely to report barriers 
to optimal service delivery, including lack of full-time or paid staff, funding, and problems 
recruiting participants. (Des Jarlais et al., 2015) With increased heroin overdoses, a recent 
outbreak of HIV among PWID in a rural community, and a reported increase in vulnerability to 
the spread of HIV and HCV among PWID in rural counties, it is apparent there is a need for 
more SEPs and harm reduction services in rural areas of the US. (Conrad, Bradley, Broz, 
Buddha, Chapman, Galang, Hillman, Hon, Hoover, Patel, Perez, Peters, Pontones, Roseberry, 
Sandoval, Shields, Walthall, Waterhouse, Weidle, Wu, Duwve, et al., 2015; Rudd, Seth, et al., 
2016; Van Handel et al., 2016) 
2.4  West Virginia 
West Virginia (WV) is a rural state in central Appalachian with a decreasing population 
currently at 1.8 million. In terms of sociodemographic characteristics, WV is a predominantly 
white and non-Hispanic (93.6%) state that has an unemployment rate of 6% and almost 1 in 5 
persons living in poverty. (Statistics, 2017; "United States Census Bureau: Statistical Abstract of 
the United States: 2011 (130th Edition)," 2011). 
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2.4.1 Drug Overdoses 
 Compared to the rest of the US, West Virginia has the highest opioid ODD rate at 41.5 
deaths per 100,000 people with Kentucky as the next closest at 34.3 deaths per 100,000. (CDC 
National Vital Statistics System, 2016) The WV age-adjusted ODD rate has increased 10-fold 
since 1999, and by 16.9% since 2014.  Among states reporting information on prescription and 
heroin ODDs, WV ranks as one of the highest nationally, with rates of 19.8 deaths and 11.8 
deaths, respectively, per 100,000 people. (CDC National Vital Statistics System, 2016) 
2.4.2 IDU Associated Infectious Diseases 
As of 2014, WV has the second highest rate of HCV and the highest rate of HBV in the 
US at 3.4 per 100,000 and 10.1 per 100,000 respectively with additional studies showing a 
continuing increase among IDUs. (CDC, 2014; Harris et al., 2016; Van Handel et al., 2016; 
Zibbell, Iqbal, Patel, Suryaprasad, Sanders, Moore-Moravian, Serrecchia, Blankenship, Ward, 
Holtzman, et al., 2015)  Notably, the HBV rate is nearly triple that of the next highest state, 
Kentucky, which reported 3.7 cases per 100,000 people in 2014. (CDC, 2014) Despite these 
disproportionately high rates of HCV and HBV, state HIV surveillance data shows one of the 
lowest rates of new HIV infections at 4.7 cases per 100,000 people. (CDC, 2016)  However, 
considering the upward trend of HCV and HBV rates among PWID, increases in HIV rates may 
follow as a result of overlapping risk factors.  
2.4.3 Care access  
 Access to care, especially infectious disease care is limited to the larger cities.  Further, 
many of the barriers that inhibit the utilization of care and services in rural regions of the US are 
likely to affect similar areas in WV. Consequently, high-risk populations especially, like PWID, 
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have fewer options for healthcare, and may have worse outcomes. One way the state Department 
of Health and Human Resources (DHHR) attempts to combat these issues is through bolstering 
infectious disease testing. According to a recent health advisory, the WV DHHR recommended 
screening for HIV, HCV, and HBV routinely and simultaneously, reporting clusters of HIV 
within 24 hours, and providing screening and counseling. Specifically, the WV DHHR 
recommends testing and counseling be conducted in opioid substitution therapy programs (e.g. 
methadone), buprenorphine-prescribing facilities, drug rehabilitation or detoxification programs, 
mental health service providers for substance use disorder, harm reduction and syringe service 
programs, emergency departments and in-patient settings, jails and prisons. Although screening 
is important, investing in and expanding coverage of interventions specific to PWID, like harm 
reduction, could reduce the impact of IDU in West Virginia. (DHHR, 2017) 
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C H A P T E R  3 :  M E T H O D S  
3.1  Participants 
 Secondary data from Medicaid-insured individuals residing in West Virginia diagnosed 
with conditions related to injection drug use (IDU) between the fiscal years 2014 and 2016 were 
included in this study. Medicaid eligibility is based on modified adjusted gross income relative to 
the federal poverty level (FPL). (CMS, 2017) Adults in West Virginia at 133% of the FPL are 
automatically eligible for Medicaid coverage. The International Classification of Diseases-
Revision 10 (ICD-10) was used to assess IDU within this population, as well as comorbid 
conditions relating to IDU. The time period for this study was chosen because the state Medicaid 
expansion coverage under the Affordable Care Act (ACA) began January 1, 2014.  Any 
individuals under the age of 18 were excluded from these analyses.  
3.2  Measures 
 The classification of IDU and associated comorbid conditions were based on a 
predetermined list of ICD-9 and 10 codes. Both ICD-9 and 10 codes were used because WV 
switch from ICD-9 to -10 in 2015.  Since few, if any, ICD-9 or 10 codes relate specifically to 
IDU and infections arising from IDU, a previously established framework was used to define 
these measures in this study. (Tookes et al., 2015) This framework defines IDU and related 
infections as having one or more drug abuse diagnoses with one or more infection diagnoses. 
Table 1 outlines ICD-9 and 10 codes used to determine drug abuse. Table 2 lists ICD-9 and 10 
codes used to determine IDU-related infections. Overdoses (OD) were defined according to the 
drug-specific poisoning ICD-10 code. 
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 Clinical conditions, e.g HIV, acute HCV infection, and endocarditis, were defined using 
indicator variables. Variables race and county of residence were collapsed into smaller categories 
to avoid small cell counts. Race was collapsed into black, white, other, and unknown, with other 
referring to Hispanic or native American/native Alaskan. A person’s county of residence was 
collapsed into public health district, which was defined by surveillance reports conducted by the 
West Virginia Department of Health and Human Resources (WV DHHR). Figure 1 provides a 
graph of these public health districts. 
Figure 1: West Virginia public health districts according to WV DHHR surveillance reports 
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Table 1: ICD-9 and 10 codes used to define drug abuse 
Drug Abuse 
Diagnoses 
ICD-9 Codes ICD-10 Codes 
Opiates E850.0; E850.2; 304.00-.03; 304.70-.73; 305.50-.53; 
965.01; 965.09 
F11.20-.21; F19.20-.21; F11.10; T40.1X1A-
.1X4A; T40.2X1A-.2X4A 
Cocaine 304.21-.23; 305.60-.63; 970.81 F14.20-.21; F14.10; T40.5X1A-.5X4A; 
Amphetamines 304.41-.43; 305.71-.73; 969.72 F15.20-.21; F15.10; T43.621A-.624A 
Sedatives 305.40-.43 F13.10 
Other
1
 304.60-.63; 304.80-.83; 304.90-.93; 305.90-.93; 
648.33; 648.34 
F19.20-.21; F18.10; 099.321-.323; 099.325 
 
1’Other’ includes unspecified drug dependence, combination of drug dependence, and drug dependence relating to pregnant women. 
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Table 2: ICD-9 and 10 codes used to define IDU-related infections 
Infection 
Diagnoses 
ICD-9 Codes ICD-10 Codes 
Endocarditis  112.81; 421.0; 421.1; 421.9; 424.0-.3; 424.90; 424.91; 
424.99 
B37.6; I33.0; I39; I33.9; I34.0; I34.8; I35.0 -.2; 
I35.8; I35.9; I36.0; I36.8; I37.0; I37.8; I38; I39 
Sepsis or 
bacteremia 
038.0; 038.10-.12; 038.19; 038.2; 038.3; 038.40-.44; 
038.49; 038.8; 038.9; 415.12; 422.92; 449; 785.52; 
790.7; 995.90-.92 
A40.9; A41.2; A41.01-.02; A41.1; A40.3; A41.4; 
A41.50; A41.3; A41.51-.53; A41.59; A41.89; 
A41.9; I26.90; I40.0; I76; R65.21; R78.81; R65.10; 
R65.20 
Osteomyelitis 730.00-.29; 730.90-.99 M86.10; M86.20; M86.119; M86.219; M86.129; 
M86.229; M86.139; M86.239; M86.149; M86.249; 
M86.159; M86.259; M86.169; M86.269; M86.179; 
M86.279; M86.18; M86.28; M86.19; M86.29; 
M86.60; M86.619; M86.629; M86.639; M86.642; 
M86.659; M86.669; M86.679; M86.68; M86.69; 
M86.9; M46.20; M46.30 
 
Skin or soft tissue 
infections 
040.0; 324.0; 324.1; 324.9; 326; 567.22; 567.31; 
567.38; 569.5; 572.0; 590.1; 681.00-.02; 681.10; 
681.11; 681.9; 682.0-.9; 709.8; 728.86; 723.6; 729.30; 
729.39; 785.4 
A48.0; G06.0-.2; G09; K65.1; K68.12; K68.19; 
K63.0; K75.0; N10; L03.019; L03.029; L03.019; 
L03.039; L03.049; L03.019; L03.029; L03.39; 
L03.49; K12.2; L03.211; L03.212; L03.213; 
L03.221; L03.222; L03.319; L03.129; L03.317; 
L03.811; L03.818; L03.891; L03.898; L03.90; 
L03.91; L94.2; L98.8; M72.6; M54.02; M79.3; I96 
 
HIV/AIDS 042; 079.53; 795.71; V08 B20; Z21; Z20.6 
 
Hepatitis C, Acute 070.51; 070.41 B17.10; B17.11 
 
Hepatitis B, Acute 070.21; 070.20; 070.30 B16.9; B16.1; B16.0 
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3.3  Design 
 This study was a retrospective, secondary data analysis of payer information collected on 
West Virginia Medicaid participants between the fiscal years 2014 and 2016. Requested 
variables included demographic characteristics, services rendered, and the cost of those services. 
Demographic variables included age, gender, race/ethnicity, and county of residence. Service 
variables included provider/facility type, claim type, service category, and the date the service 
was provided. Cost variables included prescription, and medical service costs. Data were housed 
on a secure drive with restricted access. West Virginia University’s Institutional Review Board 
approved the protocol for this study.  
3.4  Procedure 
 The data for this study was formally requested through the West Virginia Department of 
Health and Human Resources’ external analytic request mechanism. The data request was based 
on a pre-determined list of ICD codes which related to IDU, e.g. HCV, HIV, HBV, soft tissue 
infections, ODs, etc.  The cost of these data was $6,450.  Specific protections were employed for 
these data, and included access restrictions and storage on secure drives. Upon receiving the 
requested data, preprocessing techniques were used to clean and merge data into workable 
datasets. Data analysis followed in accordance with the aims and objectives of this study.  
3.5  Outcomes  
 The underlying goal of this dissertation project was to determine specific service 
utilization and associated costs, describe health outcomes, and develop a comprehensive profile 
of PWID in WV using statewide, individual service-level data. The outcomes for the project 
were: 1. determining the viability of state Medicaid data as a source of identifying drug 
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overdoses and drug-related infections by comparing to surveillance data using equivalence 
testing; 2. understanding the service utilization patterns and potential associations with certain 
characteristics of PWID; 3. estimating the cost attributable to specific services. Topics 
investigated under each of these outcomes included: overdoses, viral infections, soft tissue 
infections, geographic distributions, most common services accessed, and most costly services 
accessed.  
3.6  Statistical Analysis 
 Categorical variables, e.g. race, gender, service type, and clinical diagnoses, were 
described using frequency and contingency tables with counts and percentages. Spatial variables, 
e.g. county of residence and provider, were plotted using Geographic Information Systems (GIS) 
packages (‘tmap’ and ‘rgdal’) in R to assess the distribution of PWID insured by Medicaid 
within WV. Continuous variables, e.g. age, medical claims cost, and prescription claims cost, 
were summarized using mean, median, minimum, maximum, interquartile range, and skew. 
Scatterplots and histograms were utilized in order to visualize these continuous data to identify 
potential outlying subjects or clusters, and to assess skew. 
Given the size of claims data for a statewide population, asymptotic statistical tests, e.g. 
χ2 test, were used to assess relationships among the categorical variables (e.g. race and service 
types) to assess unadjusted relationships. Where there were small cell sizes (< 5), Fisher’s exact 
test replaced the χ2 test.  Pearson’s correlation coefficient was used to assess the relationship 
between continuous variables, e.g. age versus medical claims cost. In the multivariate data 
analysis, linear regression models were used for continuous outcome variables, logistic 
regression models were used for binary outcome variables and ordinal logistic regression models 
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were used for the ordinal scale outcome variables. P-values were used to comment on the 
strength of the association.  
For all formal hypothesis testing and confidence interval construction, an alpha-level of 
0.05 was used.  All analyses will be conducted using R version 3.3.3. 
3.6.1  Analyses for Specific Aim 1: 
Aim 1: Determine the efficacy of state Medicaid data as a proxy for disease surveillance data in 
estimating the number of drug overdoses and injection drug related infections in WV between 
2014 and 2016. 
 The prevalence of IDU and correlates were calculated using the requested ICD-9 and 10 
codes. In order to determine if Medicaid claims data can be used as a proxy for measuring IDU 
and associated infections in West Virginia (WV), calculated rates and/or proportions were 
compared to state estimates obtained from various surveillance data.  The full Medicaid claims 
dataset, rather than the IDU subset, was used since IDU is only one of the risk behaviors for 
HIV, HCV, and HBV.  Medicaid claims utility, as a proxy to surveillance data, was assessed 
using equivalency testing between the two data sources.  Specifically, tests for equivalency 
between Medicaid claims and surveillance data (gold standard) with an equivalence margin of 
+/- 50% change relative to state surveillance rates served as the basis for determining the 
viability of Medicaid claims data in estimating IDU. Since there is little information to support a 
specific equivalence margin for rare events, the choice to use relative percent change for an 
equivalence margin is loosely based on the CDC’s use of statistically significant changes in 
heroin OD rates between calendar years.  Table 3 reports the rates of each diagnosis according to 
state surveillance data, and the corresponding equivalence margin. 
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Table 3: Rates of injection drug use (IDU) related diagnoses obtained from 2015 state 
surveillance reports with equivalence margin of +/- 50% relative change. 
 State Surveillance Equivalence 
Margin 
Diagnoses n Rate per 100,000 +/- 50% 
Hepatitis C, acute 63 3.4 (1.7, 5.1) 
Hepatitis B, acute 272 14.7 (7.4, 22.1) 
Persons Living with HIV/AID 1,988 107.8 (53.9, 161.7) 
Heroin Poisoning 327 17.7 (8.9, 26.6) 
a
Sources: West Virginia Department of Health and Human Resources; WV Poison Center 
Annual Report 
3.6.2  Analyses for Specific Aim 2 
Aim 2: Examine service utilization and characteristics of WV Medicaid beneficiaries who inject 
drugs between 2014 and 2016. 
Service utilization was described according to inpatient, emergency room, and substance 
abuse/mental health services. Observations were categorized based on frequency of service 
utilization, with cut points indicating low, medium and high frequency usage. Cut points were 
based on previous studies investigating emergency room, inpatient, and substance abuse service 
utilization. (Lin, Bharel, Zhang, O'Connell, & Clark, 2015) For inpatient services, cut points at 
one service, two services, and three or more services accessed during the study period were used. 
For both emergency room and mental health/substance abuse services, cut points were at one to 
two services, three to five services, and six or more services. Since the outcome variable is 
naturally ordered, ordinal logistic regression was used to assess the relationship between patient 
characteristics, e.g. demographics, diagnoses, and district of residence, and frequency of service 
usage. The proportional odds assumption was assessed graphically. 
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3.6.3  Analyses for Specific Aim 3 
Aim 3: Examine the cost of service utilization of WV Medicaid beneficiaries who inject drugs 
between 2014 and 2016.  
Linear modelling of total costs for care and services was used to assess relationships with 
patient characteristics, e.g. demographics, diagnoses, service types, and district of residence. 
Two models were built, including one with an outcome variable of the total cost for medical 
services only, and one with an outcome variable of the total cost for medical services and 
prescription drugs. In both models, histograms of the outcome variables showed heavy right 
skew. Subsequently, the outcome variables were log transformed to satisfy distributional 
assumptions of multiple regression. Diagnostic plots, e.g. residual and Q-Q plots, were used to 
assess any other assumption violations. Stepwise model selection with AIC was used to obtain 
the final models. Adjusted effects were obtained from the final models to determine the highest 
costs according to patient characteristics.  These effects were back transformed to allow for 
interpretation in terms of percent change relative to the reference group.  
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C H A P T E R  4 :  R E S U L T S  
4.1  Description of Sample 
 Table 3 describes characteristics of the sample. There were 5,082 WV Medicaid 
beneficiaries identified as PWID, utilizing 14,414 services between fiscal years 2014 and 2016. 
Of these individuals, men comprised 51.6% (n=2,622) of the sample, while women accounted 
for 48.3% (n=2,457).  White race was the most common reported (60.5%; n=3,075), followed by 
‘other’ (4.6%; n=236), and black (1.9%; n=98). A large number of individuals’ race was reported 
as unknown (32.9%; n= 1,673).  The median age was 34 years (18 – 85 years), and the majority 
of persons had a plan type of fee-for-service (75.5%; n=3,822). The median total cost per person 
attributable to medical claims and prescription claims was $794.90 ($0.00 – $203,800), and 
$986.60 ($0.00 - $158,000) respectively. The median number of total services accessed per 
person was four (1 – 84), and the median number of total prescriptions per person was 28 (1 – 
616). Most individuals resided in District 2 (23.6%; n=1,197) and District 3 (20.7%; n=1,052) 
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Table 4: Characteristics of West Virginia (WV) Medicaid beneficiaries who inject drugs 
(n=5,082), 2014-2016 
Characteristic n(%) 
Gender 
   Men 
   Women 
 
2,622 (51.6) 
2,457 (48.3) 
Race 
   Black 
   White 
   Other 
   Unknown 
 
98 (1.9) 
3,075 (60.5) 
236 (4.6) 
1,673 (32.9) 
Claim Plan Type 
   Managed Care 
   Non Managed Care/Fee for 
Service 
 
1,247 (24.5) 
3,835 (75.5) 
District 
   District 1 
   District 2 
   District 3 
   District 4 
   District 5 
   District 6 
   District 7 
   District 8 
 
734 (14.4) 
1,197 (23.6) 
1,052 (20.7) 
275 (5.4) 
288 (5.7) 
332 (15.9) 
558 (11.0) 
640 (12.6) 
Total 5,082 
 Median (min – max) 
Age 34 (18 – 85) 
Medical Claims Cost $794.90 ($0.00 – $203,800) 
Prescription Claims Cost $986.60 ($0.00 - $158,000) 
Number of Services Accessed 6 (1 – 88) 
Number of Prescriptions  28 (1 – 616) 
1
Totals may not sum to 5,082 as a result of missing data.  
2
Other race defined as Hispanic or American Indian/Alaska Native 
 
Table 4 shows the geographic distribution of Medicaid insured PWID by WV county 
during the study period. Since these data are based on fiscal years, July – December is included 
for 2014, all of 2015 is included, and January – June is included for 2016. Kanawha county was 
the most commonly reported county of residence (n=770; 2014-2016), followed by Cabell 
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(n=651; 2014-2016) and Berkeley (n=361; 2014-2016). Figure 2 provides a visual representation 
of the distribution of Medicaid insured PWID within WV. 
Table 5: Number of WV Medicaid beneficiaries who inject drugs by county of residence, 2014-
2016 
County 2014 2015 2016  County 2014 2015 2016 
Barbour 9 8 3  Mineral 12 20 2 
Berkeley 84 217 79  Mingo 21 33 13 
Boone 39 43 10  Monongalia 44 76 25 
Braxton 7 10 6  Monroe 1 7 1 
Brooke 12 26 6  Morgan 3 27 5 
Cabell 175 360 140  Nicholas 15 24 6 
Calhoun 2 5 1  Ohio 42 53 28 
Clay 6 10 4  Pendleton 0 5 1 
Doddridge 2 5 0  Pleasants 1 2 1 
Fayette 32 70 19  Pocahontas 4 4 1 
Gilmer 2 3 0  Preston 13 26 10 
Grant 5 6 2  Putnam 42 59 27 
Greenbrier 15 36 11  Raleigh 100 149 45 
Hampshire 11 14 7  Randolph 21 31 12 
Hancock 38 51 17  Ritchie 1 5 1 
Hardy 5 6 4  Roane 4 12 3 
Harrison 39 59 15  Summers 15 23 5 
Jackson 12 25 8  Taylor 4 11 2 
Jefferson 39 68 18  Tucker 2 1 0 
Kanawha 250 421 141  Tyler 2 9 0 
Lewis 8 9 3  Upshur 9 14 2 
Lincoln 32 49 17  Wayne 27 67 34 
Logan 56 57 26  Webster 2 6 7 
Marion 31 40 19  Wetzel 9 7 6 
Marshall 14 17 6  Wirt 2 1 4 
Mason 28 49 13  Wood 44 111 32 
McDowell 18 50 6  Wyoming 31 27 7 
Mercer 77 130 42  TOTAL 5,079
1
 
1
Totals may not sum to 5,082 as a result of missing data. 
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Figure 2: Map of total number of WV Medicaid beneficiaries who inject drugs by county, 2015 
 
 The most common types of services accessed and patient diagnoses can be seen in Tables 
6 and 7. ‘Physician Non-Specialty Inpatient’ services had the most patient visits with 2,957 over 
the study period, followed by ‘Facility Inpatient Medical’ (n=2,783), ‘Facility Outpatient ER’ 
(n=2,099), and ‘Physician Non-Specialty ER’ (n=1,315). The most common diagnoses within 
this sample included ‘Toxic Effects of Substances’ (n=5,077), ‘Infections of the Skin or 
Subcutaneous Tissue’ (n=4,127), ‘Mental Health- Substance Abuse’ (n=2,030), and ‘Hepatitis, 
Viral’ (n=1,302).  
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Table 6: Ten most common service categories by number of patient visits among WV Medicaid 
beneficiaries who inject drugs, 2014 - 2016 
Service Category Patient Visits 
Physician Non-Specialty Inpatient 2,957 
Facility Inpatient Medical 2,783 
Facility Outpatient ER 2,099 
Physician Non-Specialty ER 1,315 
Substance Abuse Other Outpatient 772 
Physician Non-Specialty Office 
Visits 
505 
Physician Specialty ER 499 
Substance Abuse Office Visits 482 
Professional Diagnostic Services 433 
Laboratory Outpatient Other 422 
Total 12,267 
 
Table 7: Ten most common diagnoses among WV Medicaid beneficiaries who inject drugs, 
2014 – 2016. 
Diagnoses n  
Toxic Effects of Substances 5,077 
Infections/Inflammation - Skin/Subcutaneous 
Tissue 
4,127 
Infections, NEC 2,141 
Mental Health - Substance Abuse 2,030 
Hepatitis, Viral 1,302 
Cardiovascular Disorder, NEC 735 
Pregnancy without Delivery 561 
Signs/Symptoms/Other Cond, NEC 520 
Infections - Musculoskeletal 457 
Mental Health - Depression 432 
Total 17,382 
 
4.2  Specific Aim Results 
4.2.1  Specific Aim 1 
Aim 1: Determine the efficacy of state Medicaid data as a proxy for disease surveillance data in 
estimating the number of drug overdoses and injection drug related infections in WV between 
2014 and 2016. 
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 Rates per 100,000 people for all Medicaid beneficiaries are compared to state 
surveillance reported rates in Table 8.  According to Medicaid claims data, 739 beneficiaries had 
an acute HCV diagnosis, 420 had an acute HBV diagnosis, 229 had an HIV/AIDS diagnosis, and 
835 had a heroin poisoning in 2015. The year 2015 was used for these comparisons since it is the 
only year within the data that includes an entire calendar year. The denominator for the incidence 
rates among Medicaid beneficiaries was defined based on the estimate that Medicaid covers 
approximately 29% of WV. (Foundation, 2017) For each rate (e.g. acute HCV, acute HBV, HIV, 
and heroin OD), Medicaid claims data were significantly different from state surveillance data at 
the alpha level of 0.05.  
Table 8: Injection drug use (IDU) related diagnoses among all WV Medicaid beneficiaries in 
2015 compared to incidence reported by surveillance data. 
 Medicaid Beneficiaries State Surveillance
2 
Test for 
Equivalence
4
 
Diagnosis n Rate per 
100,000
1 
n  Rate per 
100,000 
p-value (95% CI)
3
 
Hepatitis C, acute 739 138.2 63 3.4 <0.001 (124.7, 
144.8) 
Hepatitis B, acute 420 78.5 272 14.7 <0.001 (56.0, 71.6) 
Persons living with 
HIV/AIDS 
229 42.8 1,988 107.8 <0.001 (57.6, 72.4) 
Heroin Poisoning 838 156.1 327 17.7 <0.001 (127.5, 
149.3) 
1
Denominator (534,760) equals 29% of West Virginians covered by Medicaid x 2015 population 
(1,844,000). 
2
Sources: West Virginia Department of Health and Human Resources; WV Poison Center 
Annual Report 
3
95% Confidence intervals are multiplied by 100,000 for interpretations 
4
P-value < 0.05 implies there is significant difference in the comparison 
 
4.2.2  Specific Aim 2 
 
Aim 2: Examine service utilization and characteristics of WV Medicaid beneficiaries who inject 
drugs between 2014 and 2016. 
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 Service utilization was described according to specific types of services, including 
inpatient, mental health/substance abuse, and emergency room services.  
Inpatient Services 
Table 9 outlines characteristics of WV Medicaid beneficiaries who received an inpatient 
service during the study period. Between 2014 and 2016, this sample of WV Medicaid 
beneficiaries had 6,280 inpatient services. Among those who had an inpatient related service, 
most were white (n=1,478; 61.3%) men (n=1,251; 51.9%), with a median age of 36 years. 
Unknown race was frequently reported for this sample (n=776; 32.2%). The most common 
clinical conditions were related to infections (n=2,889), and particularly soft tissue infections 
(n=1,481). Toxic effects of substances were also a frequently reported clinical condition (n=689).  
Most individuals with an inpatient service accessed one service during the study period 
(n=1,354; 56.2%), while 401 (16.6%) had two, and 648 (26.9%) had three or more. Table 10 
shows the adjusted associations between WV Medicaid beneficiary characteristics and the 
frequency of inpatient service utilization obtained from an ordinal logistic regression model.  
Individuals with endocarditis (aOR= 2.06, 95% CI= [1.58, 2.70]) and soft tissue infections 
(aOR= 1.71, 95% CI= [1.42, 2.07]) had higher odds of utilizing more inpatient services 
compared to those who did not. Acute HCV infection had a protective effect on having more 
inpatient services (aOR= 0.59, 95% CI= [0.39, 0.88]).  
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Table 9: Characteristics of WV Medicaid beneficiaries who received an inpatient service 
between 2014 and 2016 (n=2,411).  
Characteristic n(%) 
1
 
Total Number of Inpatient Visits 6,280 
Gender 
   Men 
   Women 
 
1,251 (51.9) 
1,159 (48.1) 
Race 
   African American  
   Other
3
 
   White 
   Unknown 
 
57 (2.4) 
99 (4.1) 
1,478 (61.3) 
776 (32.2) 
Clinical Condition
2
 
   Skin/Subcutaneous Tissue Infection 
   Other Infections 
   Toxic Effect of Substances 
   Cardiovascular Disorder 
   Viral Hepatitis 
 
1,481 
1,408 
689 
401 
231 
District 
   District 1 
   District 2 
   District 3 
   District 4 
   District 5 
   District 6 
   District 7 
   District 8 
 
334 (13.9) 
521 (21.6) 
536 (22.2) 
164 (6.8) 
146 (6.1) 
145 (6.0) 
295 (12.2) 
269 (11.2) 
 Median (min – max) 
Age (years) 36 (18 – 85) 
Number of Encounters per Person 1 (1 – 62) 
1
Totals may not add to 100% due to missing data 
2
Clinical conditions based on duplicated dataset.  
3
Other race defined as Hispanic or American Indian/Alaska Native 
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Table 10: Adjusted associations between WV Medicaid beneficiary characteristics and inpatient 
service utilization between 2014 and 2016.  
Characteristic aOR (95% CI) 
Endocarditis Infection 
   No 
   Yes 
 
Reference 
2.06 (1.58, 2.70) 
Soft Tissue Infection
 
   No 
   Yes 
 
Reference 
1.71 (1.42, 2.07) 
Acute Hepatitis C Infection
 
   No 
   Yes 
 
Reference 
0.59 (0.39, 0.88) 
Age  0.98 (0.97, 0.99) 
 
Emergency Room Services 
Table 11 summarizes the characteristics of WV Medicaid beneficiaries who inject drugs 
and received an emergency room (ER) service during the study period. Most of these individuals 
were white (n=1,290; 59.8%) men (n=1,159; 53.7%), with a median age of 33. The predominant 
clinical condition was drug poisoning (n=2,280).  Soft tissue infections were the next most 
frequent (n=949), followed by other infections (n=113), viral hepatitis (n=59) and respiratory 
disorders (n=58).  
Among WV Medicaid beneficiaries who inject drugs and received an ER service, most 
received one or two services during the study period (n=1,790; 83.0%), 327 (15.2%) received 
three to five services, and 40 (1.9%) received six or more services. Table 12 contains the 
adjusted relationships between patient characteristics and the frequency of ER service utilization. 
Individuals with endocarditis (aOR= 2.60, 95% CI= [1.20, 5.26]), soft-tissue infections (aOR= 
2.17, 95% CI= [1.48, 3.23]), or had a drug poisoning (aOR= 2.29, 95% CI= [1.62, 3.31]) had a 
higher odds of presenting for more ER services compared to those who did not.  
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Table 11: Characteristics of WV Medicaid beneficiaries who received an emergency room (ER) 
service between 2014 and 2016 (n=2,157).  
Characteristic n(%) 
1
 
Total Number of ER Visits 3,913  
Gender 
   Men 
   Women 
 
1,159 (53.7) 
996 (46.2) 
Race 
   African American  
   Other
3
 
   White 
   Unknown 
 
45 (2.1) 
122 (5.7) 
1,290 (59.8) 
700 (32.5) 
Clinical Condition
2
 
   Toxic Effect of Substances 
   Skin/Subcutaneous Tissue Infection 
   Other Infections 
   Viral Hepatitis 
   Respiratory Disorder 
 
2,280 
949 
113 
59 
58 
District 
   District 1 
   District 2 
   District 3 
   District 4 
   District 5 
   District 6 
   District 7 
   District 8 
 
216 (10.0) 
620 (28.7) 
462 (21.4) 
69 (3.2) 
133 (6.2) 
144 (6.7) 
198 (9.2) 
311 (14.4) 
 Median (min – max) 
Age (years) 33 (18 – 78) 
Number of Encounters per Person 1 (1 – 13) 
1
Totals may not add to 100% due to missing data 
2
Clinical conditions based on duplicated dataset.  
3
Other race defined as Hispanic or American Indian/Alaska Native 
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Table 12: Adjusted associations between WV Medicaid beneficiary characteristics and 
emergency room (ER) service utilization between 2014 and 2016.  
Characteristic aOR (95% CI) 
Endocarditis Infection 
   No 
   Yes 
 
Reference 
2.60 (1.20, 5.26) 
Drug Poisoning
 
   No 
   Yes 
 
Reference 
2.29 (1.62, 3.31) 
Soft Tissue Infection
 
   No 
   Yes 
 
Reference 
2.17 (1.48, 3.23) 
 
Mental Health and Substance Abuse Services 
 Table 13 highlights characteristics of WV Medicaid beneficiaries who inject drugs that 
utilized mental health or substance abuse services between 2014 and 2016. White (n=488; 
60.0%) men (n=413; 50.8%) had the most mental health or substance abuse services throughout 
the study period. The median age for these individuals was 34 years. Substance abuse (n=1,572), 
depression (n=262), bipolar disorder (n=109), other psychoses (n=53) and anxiety disorder 
(n=42) were the most frequently reported clinical conditions.  
 The majority of individuals who utilized mental health or substance abuse services had 
one or two service encounters during the study period (n=649; 80%). Comparatively, 119 (15%) 
had three to five encounters, and 45 (6%) had six or more encounters. Unadjusted and adjusted 
associations between patient characteristics and mental health and substance abuse service usage 
were explored, but no statistically significant relationships were found at the 0.05 alpha level. 
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Table 13: Characteristics of WV Medicaid beneficiaries who received a mental health and/or 
substance abuse service between 2014 and 2016 (n=813).  
Characteristic n(%) 
1
 
Total Number of Visits 2,111 
Gender 
   Men 
   Women 
 
413 (50.8) 
399 (49.1) 
Race 
   African American  
   Other
3
 
   White 
   Unknown 
 
 6 (1.0) 
 63 (7.7) 
 488 (60.0) 
 255 (31.4) 
Clinical Condition
2
 
   Mental Health – Substance Abuse 
   Mental Health – Depression 
   Mental Health – Bipolar Disorder 
   Mental Health – Psychoses 
   Mental Health – Anxiety Disorder 
 
1,572 
262 
109 
53 
42 
District 
   District 1 
   District 2 
   District 3 
   District 4 
   District 5 
   District 6 
   District 7 
   District 8 
 
171 (21.0) 
189 (23.2) 
138 (17.0) 
37 (4.6) 
48 (5.9) 
61 (7.5) 
71 (8.7) 
97 (11.9) 
 Median (min – max) 
Age (years) 34 (18 – 65) 
Number of Encounters 1 (1 – 65) 
1
Totals may not add to 100% due to missing data 
2
Clinical conditions based on duplicated dataset.  
3
Other race defined as Hispanic or American Indian/Alaska Native 
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4.2.3  Specific Aim 3  
Aim 3: Examine the cost of service utilization of WV Medicaid beneficiaries who inject drugs 
between 2014 and 2016.  
 
 The total cost of medical services for this sample was $18,473,217, and the total cost for 
prescriptions was $154,789,571. The most commonly accessed services for this sample and the 
associated costs are listed in Table 14. Inpatient services incurred the highest cost for this sample 
during the study period. Specifically, ‘Facility Inpatient Medical’ services accounted for 
$14,390,988.00, nearly 18 times costlier than the next highest service type (Mental Health 
Inpatient; $805,993.30). ‘Facility Outpatient ER’ ($779,515.90), ‘Facility Inpatient Long Term 
Care’ ($656,044.90), and ‘Substance Abuse Inpatient’ ($420,346.50) also accounted for a large 
proportion of the total costs for this sample. 
 Results from the multiple regression models are shown in Tables 15 and 16. In the first 
model, where the outcome was the natural log of the cost for medical services, while controlling 
for other covariates, men cost 16% more than women; individuals with endocarditis cost 18% 
more than those without; individuals with acute HCV infection cost 16% more than those 
without; individuals with acute HBV infection cost 53% more than those without; and 
individuals residing in District 5 cost 84% more than those living in District 3 (reference). The 
second model, in which the outcome was the natural log of the total cost of medical services and 
prescription drugs per person, men cost less than women (24.6% decrease), while those with 
HIV (281% increase) and endocarditis (48.5% increase) cost more than those not infected.  
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Table 14: Commonly accessed services among WV Medicaid beneficiaries who inject drugs and 
associated costs (2014-2016). 
Service Type Visits (n) Total Cost 
Facility Inpatient Long Term Care 105 $656,044.90 
Facility Inpatient Maternity 108 $241,074.40 
Facility Inpatient Medical 2,783 $14,390,988.00 
Facility Inpatient Non Acute 8 $10,746.44 
Physician Specialty Inpatient 319 $38,169.89 
Physician Non-Specialty Inpatient 2,957 $436,426.60 
Inpatient Total
1
 6,280 $15,773,450.23 
Facility Outpatient ER 2,099 $779,515.90 
Physician Non-Specialty ER 1,315 $130,140.30 
Physician Specialty ER 499 $59,833.30 
Emergency Room Total 3,913 $969,489.50 
Mental Health Inpatient 335 $805,993.30 
Mental Health Office Visits 68 $4,375.71 
Mental Health Other Outpatient 136 $24,845.67 
Mental Health Total 539 $835,214.68 
Substance Abuse Inpatient 318 $420,346.50 
Substance Abuse Office Visits 482 $27,428.39 
Substance Abuse Other Outpatient 772 $74,809.86 
Substance Abuse Total 1,572 $522,584.75 
TOTAL 12,304 $18,100,739.16 
1
Not including Mental Health or Substance Abuse Inpatient services. 
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Table 15: Relationships between characteristics of WV Medicaid beneficiaries who inject drugs 
and the natural log of total cost per medical service encounter (US Dollars). 
Characteristic  Coefficient (95% 
CI) 
% Change vs. 
Reference 
Service Type 
   Inpatient 
   Emergency 
   Mental/Substance Abuse 
   Other 
 
Reference 
-1.12 (-1.20, -1.05) 
-1.30 (-1.39,  1.20) 
-2.39 (-2.47,  -2.31) 
 
Reference 
-67.5% 
-72.6% 
-90.8% 
Age (years) 0.01 (0.01,  0.02) 1.5% 
Gender 
   Women 
   Men 
 
Reference 
0.15 (0.10, 0.21) 
 
Reference 
16.9% 
Race 
   White 
   Black 
   Other
1
 
   Unknown 
 
Reference 
-0.16 (-0.36, 0.03) 
-0.13 (-0.25, 0.00) 
-0.11 (-0.17, -0.04) 
 
Reference 
-15.2% 
-12.0% 
-10.1% 
District 
   District 3 
   District 1 
   District 2 
   District 4 
   District 5 
   District 6 
   District 7 
   District 8 
 
Reference 
0.29 (0.19, 0.38) 
0.19 (0.11, 0.28) 
0.27 (0.13, 0.41) 
0.61 0.48, 0.75) 
0.50 (0.37, 0.63) 
0.31 (0.21, 0.41) 
0.19 (0.09, 0.29) 
 
Reference 
33.2% 
21.3% 
30.7% 
84.7% 
65.2% 
36.4% 
21.3% 
Endocarditis Infection 
   No 
   Yes 
 
Reference 
0.17 (0.06, 0.27) 
 
Reference 
18.1% 
Acute HBV Infection 
   No 
   Yes 
 
Reference 
0.53 (0.39, 0.66) 
 
Reference 
69.0% 
Adjusted R
2
=0.2379 
1
Other race defined as Hispanic and American Indian/Alaska Native 
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Table 16: Relationships between characteristics of WV Medicaid beneficiaries who inject drugs 
and the natural log of the combined total cost of medical services and prescription drugs per 
person (US Dollars). 
Characteristic  Coefficient (95% 
CI) 
% Change vs. 
Reference 
Service Type 
   Inpatient 
   Emergency 
   Mental/Substance Abuse 
   Other 
 
Reference 
-1.14 (-1.27, -1.01) 
-0.22 (-0.38, -0.05) 
-0.77 (-0.92, -0.63) 
 
Reference 
-68.1% 
-19.6% 
-53.8% 
Age (years) 0.03 (0.02, 0.04) 3.1% 
Gender 
   Women 
   Men 
 
Reference 
-0.28 (-0.39, -0.18) 
 
Reference 
-24.6% 
Endocarditis Infection 
   No 
   Yes 
 
Reference 
0.40 (0.16, 0.63) 
 
Reference 
48.5% 
HIV Infection 
   No 
   Yes 
 
Reference 
1.34 (0.98, 1.69) 
 
Reference 
281.0% 
Adjusted R
2
=0.1861 
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C H A P T E R  5 :  D I S C U S S I O N  
 This dissertation had three primary aims. The first aim was to determine the efficacy of 
state Medicaid data as a proxy for disease surveillance data in estimating the number of drug 
overdoses and injection drug related infections in WV between 2014 and 2016. The prevalence 
rates for HIV, acute HCV, acute HBV, and heroin overdoses (OD) according to West Virginia 
(WV) Medicaid claims data are reported in Table 8. Each prevalence rate was significantly 
different from state surveillance rates at the alpha level of 0.05.  This result indicates that ICD 
codes from a Medicaid claims database are not a suitable proxy for state surveillance. The likely 
reason for the large discrepancy between these data sources with regards to acute HCV, acute 
HBV, and HIV is the inability to determine whether the case is new with ICD codes. 
Consequently, the prevalence rates as determined by Medicaid claims data were likely 
overestimations. As for heroin ODs, the Poison Control Center monitors OD rates that are 
reported to it passively. However, reporting heroin ODs is not mandated in WV, as it is with new 
cases of acute HCV, acute HBV, and HIV.  Therefore, it is possible that the heroin OD 
prevalence rate from the Poison Control Center is an underestimation of the true rate. Similarly, 
the heroin OD rate from Medicaid claims data is also possibly underestimating the prevalence 
since not every person who injects drugs (PWID) is insured by Medicaid. (Tookes et al., 2015) 
The second aim of this dissertation project was to describe service utilization among WV 
Medicaid beneficiaries who inject drugs. Three service types were specifically investigated for 
this project, including inpatient, emergency room (ER), and mental health and substance abuse 
services.  
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Of the service types, inpatient services were the most frequently utilized with 2,411 
people accumulating 6,280 visits between July 2014 and June 2016. The southern part of WV, 
including Districts 1 (13.9%), 2 (21.6%), and 3 (22.2%) had the most individuals accessing 
inpatient services. Comparable numbers of men (51.9%) and women (48.1%) utilized inpatient 
services, while white race (61.3%) was the most frequently reported.  Infectious diseases, 
including soft tissue infections (n=1,481) and viral hepatitis (n=231), were the most common 
conditions reported among those receiving inpatient services. When examining adjusted 
relationships between patient characteristics and frequency of service utilization obtained via 
ordinal logistic regression, infectious diseases again were consequential.  Specifically, those with 
endocarditis infection had a 2.06 times higher odds of receiving three or more inpatient services 
during the study period compared to receiving two services or less. Similarly, individuals with a 
soft tissue infection had a 1.71 times higher odds of receiving three or more inpatient services. 
Infectious diseases, like endocarditis and soft tissue infections, are largely preventable through 
the use of clean injecting equipment. Harm reduction strategies, like syringe exchange programs 
(SEPs), have proven to be effective in reducing the incidence of these types of infectious 
diseases by supplying clean injection equipment and other services. (Bastos & Strathdee, 2000; 
Kwon et al., 2009; Moss & Munt, 2003; Vickerman et al., 2006; D. P. Wilson et al., 2015) 
Reducing soft tissue and endocarditis infections, among others, could possibly reduce the use of 
inpatient services, which are generally associated with higher costs. (Tookes et al., 2015)  
ER services were the second most commonly accessed service type for this sample, with 
2,157 people presenting to the ER 3,913 times during the study period. There were slightly more 
men (53.7%) than women (46.2%), and white race (59.8%) was the most commonly reported 
among those accessing ER services. Similar to inpatient services, the southern Districts 2 
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(28.7%) and 3 (21.4%) had the largest number of individuals utilizing the ER. Similar to 
previous studies, drug poisonings (n=2,280) accounted for the largest proportion of ER services 
accessed, and were 2.4 times more frequent than the next clinical condition (soft tissue 
infections; n=949). (Backmund, Schuetz, Meyer, Edlin, & Reimer, 2009) Adjusted associations 
further showed that drug poisonings were associated with more frequent ER usage. Individuals 
with a drug poisoning had a 2.29 times higher odds of having six or more ER services compared 
to three to five services, and one to two services. Similar to inpatient services, endocarditis 
(aOR= 2.60) and soft tissue infections (aOR= 2.17) were also associated with more ER service 
usage. This study is in agreement with previous studies show that PWID tend to use the ER 
frequently. (Fairbairn et al., 2012; Palepu et al., 2001) As with inpatient services, infectious 
diseases were a large component of frequent ER service utilization within this sample. Increasing 
access to preventative care for PWID may serve to reduce frequent service utilization, and 
thereby reduce cost.   
Mental health and substance abuse services were accessed 2,111 times by 813 WV 
Medicaid beneficiaries who inject drugs during the study period. Approximately equal numbers 
of men (50.8%) and women (49.1%) utilized mental health and substance abuse services, while 
white race (60.0%) outweighed all others. As with inpatient and ER services, the southern 
districts, including 1 (21.0%), 2 (23.2%), and 3 (17.0%), had the most individuals accessing 
mental health and substance abuse services. Mental health conditions relating to substance abuse 
(n=1,572), depression (n=262) and bipolar disorder (n=109) were the most commonly reported. 
Adjusted relationships between patient characteristics and frequency of mental health and 
substance abuse service usage were explored, but yielded no statistically significant relationships 
at the alpha level of 0.05.  
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The third aim of this dissertation project was to describe the cost of service utilization 
among WV Medicaid beneficiaries who inject drugs. The total cost for medical services and 
prescription drugs was $18,473,217 and $154,789,571, respectively. Similar to Aim 2, cost was 
described according to inpatient, ER, and mental health and substance abuse services. Congruent 
with current literature, inpatient services were the costliest. (Tookes et al., 2015) A total of 6,280 
inpatient services during the study period accumulated $15,773,450.23 in charges. In other 
words, inpatient services, not including mental health or substance abuse inpatient services, 
accounted for 87% of the total cost for medical services accessed by this sample ($18,473,217) 
during the entire study period.  Also, mental health specific services had far fewer visits than any 
other service type, yet cost a similar amount compared to ER and substance abuse services.  
Two separate multiple regression models were constructed to examine the relationship 
between patient characteristics and cost. The first included the natural log of cost for medical 
services only, and the second included the natural log of cost for medical services and 
prescription drugs. In the first model (medical costs only), while controlling for other covariates, 
inpatient services were shown to cost significantly more than any other service type. Also, every 
district cost significantly more than District 3 (reference). District 3 was chosen as the reference 
because is the most populated area of WV. Infectious diseases, e.g. endocarditis (18.1% 
increase), and acute HBV infection (69.0% increase), were also associated with higher service 
costs. In the second model (medical and prescription costs), HIV infection was associated with 
significantly large increase in cost. Individuals with HIV cost 281% more than their counterparts. 
These results further support the need to increase access of preventative services, like SEPs and 
vaccinations, to reduce morbidity and cost within the injection drug use (IDU) population. As 
mentioned, many common infections among PWID are preventable given access and subsequent 
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utilization of these services, and the cost of providing such services is cost effective. Further, 
while HIV infection is associated with multiple risk behaviors other than IDU, SEPs can serve to 
reduce HIV risk among PWID. (D. P. Wilson et al., 2015)   Model fit was assessed via 
diagnostic plots, e.g. Q-Q normality plots and residuals plots, and it was determined that no 
major assumption violations occurred.  The adjusted R
2
 for the first model was 0.2379 and 
0.1861 for the second.  
5.1  Limitations 
 The goal of this dissertation project was to determine specific service utilization and 
associated costs, describe health outcomes, and develop a comprehensive profile of PWID in 
WV using statewide, individual service-level data. Few, if any studies, have investigated IDU at 
the state level using this methodology.  However, there were limitations to this project.  
First, Medicaid claims data come from an administrative database, and are not directly 
intended for research. Consequently, some variables did not contain an ideal level of 
information, or had missing information.  For instance, nearly 33% of individuals in this dataset 
had an ‘unknown’ race reported. This likely affected the estimates obtained from various models, 
and thus limited the interpretations. Also, this project’s methodology hinged on the use of ICD 
codes to identify IDU and associated conditions. This is a limitation for various reasons, 
including the tendency for ICD codes to underestimate prevalence of certain conditions. (G. 
Jones et al., 2012) Also, while the framework for identifying IDU was based on a previous study 
(Tookes et al., 2015), it is possible that misclassification on case status (IDU) occurred since it is 
not possible to directly identify IDU with ICD codes. The study period for this project also 
overlapped with the transition between ICD-9 and ICD-10 codes. While both were included in 
the analysis, the cross-walk between revisions may not be 100% 
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This study is also limited in that the project sample only included those who were insured 
by Medicaid. Although Medicaid is the largest insurer for WV, and studies report that a large 
number of PWID are covered by Medicaid, this study has limited generalizability outside of the 
WV IDU Medicaid population. (Foundation, 2017; Takahashi et al., 2010; Tookes et al., 2015) 
In addition, many PWID do not have insurance coverage, and possibly have different 
characteristics compared to those who are insured.  
For Specific Aim 2, ordinal logistic regression was used to determine relationships 
between patient characteristics and frequent service usage. One of the underlying assumptions 
for this type of model is the proportional odds assumption, or that the relationship between a 
predictor and each level of the outcome variable are the same. Assessment of this assumption 
showed that some variables were questionable, while others were appropriate. Violation of this 
assumption would indicate that the effect of a variable is different according each level of the 
outcome. This may warrant a different model, e.g. partial proportional odds model, which relaxes 
the proportional odds assumption.  
5.2  Future Research 
 Results from this project warrant further research.  Given the results from Aim 1, 
procedure codes, which identify specific surgical, medical, or diagnostic activities, may provide 
more information to help identify new cases of acute HCV, acute HBV, and HIV in 
administrative databases. If effective in identifying new cases, administrative data could provide 
information on individuals who cross state lines for medical care, and in turn improve 
surveillance for these conditions.  
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  Different statistical models for investigating the relationship between patient 
characteristics and frequency of service utilization (Aim 2) are recommended. The partial 
proportional odds model relaxes the limiting proportional odds assumption, but complicates 
interpretations. Another method may be to treat frequency of service utilization as a count 
variable, and employee negative binomial regression to explore relationships.  
 Medicaid data was used for this project because it is the largest insurer of WV and is 
reportedly one of the largest insurers of PWID. However, generalizability to PWID who are not 
covered by Medicaid is limited. Therefore, other data sources may be considered. Hospital 
discharge data, for example, provide an array of information, including diagnosis codes, 
procedure codes, cost, and demographics. Additionally, hospital discharge data includes 
information on all-payer types. Using hospital discharge data may serve to improve external 
validity.  
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